🇺🇸 FDA
Patent

US 11028392

Compositions and methods for inhibiting expression of the ALAS1 gene

granted A61KA61K9/0019A61P

Quick answer

US patent 11028392 (Compositions and methods for inhibiting expression of the ALAS1 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K9/0019, A61P, A61P1/16, A61P25/00